• Recruiting

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

Updated: May 23

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy

MGUS


rifaximin-mgus

Rifaximin in Patients With Monoclonal Gammopathy


This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.


IgA Monoclonal Gammopathy

IgG Monoclonal Gammopathy

IgM Monoclonal Gammopathy

Light Chain Deposition Disease

Monoclonal Gammopathy

Smoldering Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia

Gammopathy, Monoclonal

Gammopathy Igg


Sponsor

Emory University


Collaborator

The Leukemia and Lymphoma Society


Location

United States, Georgia

 

ClinicalTrials.gov Identifier: NCT03820817


Official Title: Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy

First Posted : January 29, 2019


https://clinicaltrials.gov/ct2/show/NCT03820817

 

Drug: Rifaximin

 

Location

United States, Georgia

Posts Archive